The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of ...

The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically ...

Lugano, Switzerland, 23 May 2025 – The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that ...

The updated phase II CYPIDES trial results presented at ESMO 2024 showed that opevesostat (ODM-208/MK-5684), an oral CYP11A1 inhibitor, demonstrated promising PSA and RECIST responses in heavily ...

Based on 18 Wall Street analysts offering 12 month price targets forBioNTech SE ADR - Dist in the last 3 months.